Connect with us

Breaking

Here are our three top medical technology companies for 2018

Published

on

Prev1 of 2
Use your ← → (arrow) keys to browse

(FinancialPress) – It’s 2018, and once again, the market is in love with medical technology.

Medical devices -the med-tech sector- have been a top performer for the last five years running. Even better than biotech. And 2018 is more of the same.

The med-tech bull is loose again!

Medical devices beat the S&P by 103%, trounce biotechs, too!

You Know Where to Go, Now Zero In

There’s never been a better way to scoop up winners than to find the best companies in the market’s hottest sectors.

That’s why you should turn your attention to Zenosense, Inc. (OTCQB: ZENO), Thermo-Fisher (NYSE: TMO)and Merit Medical Systems (NASDAQ: MMSI).

This is how it goes when med-tech is running high… Look at these gains in less than two years!

  • AxoGen is up 512% in 21 months
  • Novocure is up 266% in the last 14 months 2017
  • Cutera has risen 372% in the past 20 months

And you don’t have to wait for winners, either. The S&P 500 is down 1% to start 1Q 2018, but 26 med-tech stocks are already showing off double-digit gains!1

Take Heart with This…

If you are drawn to potential like this, it doesn’t get any more exciting than
Zenosense, Inc. (OTCQB: ZENO).

Zenosense, through a joint venture ownership in MIDS Medical Ltd, is developing a revolutionary hand-held device to diagnose heart attacks when the chance to save lives is greatest — in the first minutes of the golden hour, as soon as it happens.

This is “point-of-care” technology, the best possible medical approach. It means that whoever responds to a cry for help, paramedics, an emergency clinic, rescue squad, or nurse, can use the Zenosense device to put the patient on the right track within minutes. No need to wait as the clock ticks down for lab tests to come back, no need to worry during a 20–30-minute ambulance ride to wonder what’s really happening.

On June 19, the company released news of breakthrough quantitative product testing results. It was the culmination of seven months work. ZENO “watchers” were primed to buy…and when ZENO shares opened at around 27¢ that day…they started buying.

What happened next was breathtaking; ZENO soared from 27¢ at open to closeat 55¢

Shareholders doubled their money in just one day!

And here’s the kicker…the following day ZENOhit a high of 77¢, which pushed it to a triple off the prior day’s open of 27¢!

It doesn’t happen like this every time, but when it does, you can lock in some impressive gains very quickly!

And just so you know, despite this big two-day gain, we see massive upside potential in Zenosense as it moves ever closer to a final product announcement. Now may be the ideal time to consider a position in ZENO…at a minimum, make sure that ZENO is on your watch list.

Now could be the ideal time to jump in; we believe the company has already achieved key milestones in its R&D.

Previous Milestones

(Mar, 17): Zenosense, Inc.: MIDS Medical Engages Future Diagnostics for Assay Consulting Services

(Jun, 2017): Zenosense, Inc. has received notice of a patent issuance in the U.S.

(Jul, 2017): Zenosense, Inc. — MIDS Hybrid Strip Detection Testing to Commence

These R&D milestones set the foundation for recent achievements that have firmly validated the company’s technology and moved it well along toward final stages of product development and market release.

Recent Milestones

(Nov, 2017): Zenosense, Inc.: MIDS Hybrid Strip — Successful Initial Test Results

(Jun, 2018): Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results

At this point we see these announcements as key signals to investors. Zenosense now appears poised for the kind of explosive growth that we reference above. We therefore recommend you consider ZENO as an immediate buy.

For more conservative investing in medical technology, we also recommend you consider two other healthcare opportunities. The first is an established blue-chip industry leader ThermoFisher (TMO) and the second a reliable growth-oriented mid-cap stock like Merit Medical Systems (MMSI).

ThermoFisher is a leading scientific research company that is incorporating advances in genetics into its diagnostic tools. We see tremendous upside in this arena. Further, ThermoFisher’s leadership across in multiple medical technologies makes it a reliable long-term play — but also consider that this company could be a nice 25%-30% gainer in 2018.

Merit Medical Systems (MMSI) makes disposable medical devices used particularly in cardiology, radiology and endoscopy procedures. Medical disposables have such high margins that some medical device makers earn more on the supplies for their machines than they do on the hardware itself. MMSI also has good potential for 25% to 30% before the year is out.

What to do now…

Do your homework of course. Put these three companies on your Watch List so you will get bulletins each time they make news!

But don’t dither waiting for lightening to strike. You’ll get burned that way. Med-tech stocks can move strongly and suddenly upward on good news.

ZENO’s Market Potential and Position Among the Competition

The global market for cardiac biomarker diagnostic tests is projected to reach $7.2 billion by 2018.

Several other companies are working to overcome the slow turnaround time for results from laboratory analyzers, including Abbott (NYSE:ABT), Roche (SIX:ROG), Alere (NYSE:ALR), and Trinity Biotech (NASD:TRIB). But none of them promises a true high-sensitivity instrument for instantaneous point of care diagnostics like the Zenosense MIDS Cardiac device is developing now.

For example Abbott (now the largest diagnostic company in the world with their acquisition of Alere) acquired i-Stat Corporation for $392 Million in 2003, (an amount which represents over 30X Zeno’s current value!).

i-Stat Corporation specialized in a hand-held blood analyzer for bedside testing and Abbott launched the i-Stat Troponin-I test for cardiac events in 2004. But that doesn’t mean it’s a true competitor to ZENO, because I-Stat cannot match the results of state of the art laboratory analyzers during the early onset of symptoms.

Even with that limitation, the need is so great that i-Stat is now Abbott’s leading handheld device and is used in more than one-third of all U.S. hospitals and emergency rooms.5 Imagine what will happen when a truly accurate ZENO device could be available!

ZENO Is Unique

Being developed to be considerably more accurate that the i-Stat… ZENO’s device is a standout among massive competition.

For instance, Trinity Biotech, which claimed its device was “significantly more accurate than the current established point-of-care tests in the market”6 applied for FDA approval, but it didn’t go well. At the FDA’s request, Trinity abandoned its pursuit, admitting its device could not match the performance of the most recently cleared laboratory analyzer.

That leaves an enormous market opportunity ahead for a device like MIDS Cardiac™, which would not only deliver rapid results but become the first device on the market that also delivers true high sensitivity results equal or exceeding laboratory accuracy.

Headquartered at Sci-Tech Daresbury, a world-class science and innovation campus located in the UK the ZENO development team has over thirty years cumulative experience in magnetic sensors in the medical and bioengineering field.

Faster growth — Sci-Tech Daresbury companies have seen sales grow at 30%/year over the past 5 years

More investment — Daresburg companies raised over 80m to date.

500 new products and services in the last 4 years

Incorporating the patented MIDS technology, MIDS Cardiac™ uses highly sensitive, custom built “Hall Effect” magnetic sensors embedded within a disposable microfluidic test strip as a “Lab-On-Chip” device.

This can detect extremely low levels (nano-Tesla) of magnetic field disturbance caused by the test particles used in immunoassay tests. That is what makes MIDS Cardiac™ different from anything else on the market. Detection at these levels is unheard of and should allow accuracy and speed of results, which will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected AMI.

That’s why the ZENO team scientists give this small company such an edge:

Nasser Djennati
Chief Scientific Officer
MIDS Medical Ltd.

20 years expertise in Hall Effect technology and magnetic field measurement

Nanoparticle and sensor design for bio-medical and bio-sensing medical Point of Care devices.
We’ve already told you the MIDS device is striving to achieve gold-standard results right at the point of care. That alone will make it unique and open a huge slice of the cardiac healthcare market to ZENO.

But there’s a lot more behind this product’s likely future success that makes it a game changer for emergency medicine:

A game-changing Point of Care sensitivity and accuracy improvement, equal or superior to high sensitivity cardiac biomarker assays performed on central laboratory analyzers

Patient friendly, tiny finger prick sample rather than treated venous blood draw

An industry leading tiny 5 microliter blood sample, 3 to 400 times smaller (1 assay) than existing Point of Care devices for cardiac marker tests

Test times 3 to 7 times faster (1 assay) than existing Point of Care devices

Capable of 3 multiplexed assays (3 cardiac biomarkers in a single test strip)

Automated operation by minimally trained personnel even in an ambulatory setting

Considerably more cost effective for healthcare providers than existing test devices

Conclusion — There Are Three Great Stocks Here

We like Thermo Fisher, especially for a conservative portfolio. And we believe MMSI’s growth rate should help it to do very well this year, though we have less faith in the longer term.

But we think investors looking for a home run should be excited about ZENO’s prospects.

We believe that a technology that can match or exceed state-of-the-art laboratory accuracy and deliver results rapidly in a cost-effective device the size of an average smart phone will be in universal demand. That’s what ZENO is promising, and could deliver.

Not only would ZENO’s device, the MIDS Cardiac™ meet a critical medical need for the first time, it would undoubtedly attract a very substantial valuation.

Here, i-Stat serves as a useful aid for diagnosis. Its device falls well short of the state of the art laboratory analyzers, and yet, it can command a price tag of nearly $400 million. That suggests that an enormous valuation for MIDS Cardiac™ is achievable.

If the MIDS Cardiac device succeeds as we expect, the long term could be even more dynamic. By adapting the MIDS technology to numerous other immunoassay tests, ZENO could access a market that is projected to be worth $23.7 billion per year worldwide by 2019.

With unheard accuracy levels and industry leading features on every level MIDS Cardiac™ is a true blockbuster in the making and ZENO has potential to be the high growth stock of 2018 and way beyond.

For news releases from Thermo Fisher, go to:
http://ir.thermofisher.com/investors/contact-information/email-alerts/default.aspx

For news releases from Merit, go to:
https://www.merit.com/investors/investor-information-request/

For news releases from ZenoSense, go to:
https://www.zenosense.com/investors-info

DISCLAIMER

This financial news and information portal (newbiotechstock.com), and/or our newsletters contain commercial advertisements, and are for general entertainment purposes only. Along with the aggregation of timely financial news, we are engaged in the business of analyzing, marketing and advertising companies for monetary compensation. Unless otherwise stated below, the paying Third Party for our services may own shares and may liquidate them during any and all advertising periods. This disclaimer is to be read and fully understood before using newbiotechstock.com, or joining one of our newsletter/email lists. We also encourage you to read the SEC INVESTOR ALERT before reading content found on newbiotechstock.com and/or our newsletters. You are reading content found on our financial news and informational portal because you have clicked on an advertisement found on one of many marketing channels we advertise on. newbiotechstock.com is for entertainment purposes only. We are NOT a source of unbiased information. Never invest in any stock featured on our site or newsletters unless you can afford to lose your entire investment. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled on the website/newsletter and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead, newbiotechstock.com strongly urges you to supplement the information obtained from this website/newsletter with a complete and independent investigation of the companies discussed and a consideration of all pertinent risks. Investing in securities, including the securities of the companies profiled or discussed on this website/newsletter, is highly speculative and carries a high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies discussed. The information found on newbiotechstock.com, and/or our newsletters are based on sources, which we believe to be reliable, but are not guaranteed by us as being accurate and do not purport to be a complete statement or summary of the available data. newbiotechstock.com encourages readers and investors to supplement the information found on our site or in our newsletters with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources. newbiotechstock.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the featured companies None of the owners of newbiotechstock.com, or any of its directors, officers, employees, contractors, or affiliates is a licensed broker-dealer, account representative, market maker, investment banker, investment advisor, analyst or underwriter in any jurisdiction whatsoever. newbiotechstock.com does not offer such advice or analysis, and newbiotechstock.com further urges you to consult your own independent tax, business, financial and investment advisors before purchasing or selling any securities of the companies discussed on this website/newsletter. Compensation: newbiotechstock.com may be compensated for up to one hundred thousand USD via bank wire by a third party for continuous analyzing, marketing and advertising services. newbiotechstock.com does not own any shares of any featured company. The paying third party may own shares and may sell all, any or none of any shares held in any featured company during advertisement periods, which may negatively affect the featured company’s stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the featured company. newbiotechstock.com and its employees, contractors, officers, directors, or affiliates may purchase shares on the open market of any mentioned featured company during advertisement periods and following the dissemination of any newsletters. This is an inherent conflict of interest. The services provided by this website/newsletter and its contents are provided “as is” and newbiotechstock.com makes no representations or warranties of any kind with respect to this website/newsletter, its contents or its services. This website/newsletter has been prepared solely for the purpose of providing information about newbiotechstock.com and the services it offers. This website/newsletter has been compiled in good faith by newbiotechstock.com. newbiotechstock.com assumes no liability or responsibility for any errors or omissions in the content of this website/newsletter, any failures, delays, or interruptions in its services or any content contained on this website/newsletter, any losses or damages arising from the use of the content provided on this website/newsletter, or any conduct by users of newbiotechstock.com’s services. newbiotechstock.com reserves the right to add, modify or delete any information at this website/newsletter at any time. This website/newsletter may contain “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that includes everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made in this report. Further specific financial information, filings, and disclosures as well as general investor information about the profiled companies, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org.newbiotechstock.com undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise. In addition to information about the company discussed, from time to time, this website/newsletter may contain the symbols of companies and/or news feeds or links to websites about companies that are not being discussed by us but are merely illustrative of certain activity in the stock market that we are highlighting (so-called hyperlinks to third party websites or access to third party content). Readers are advised that all links and access to these sites and content solely for informational purposes. newbiotechstock.com, its owners, directors, officers, employees, affiliates, and contractors are not responsible for errors and omissions nor does newbiotechstock.com control, endorse, or guarantee any content found in such sites or content. Any opinions expressed are subject to change without notice. It is also possible that the companies discussed on those sites may not have approved certain or any statements within the report. By accessing or viewing this website/newsletter, you agree that newbiotechstock.com, its owners, directors, officers, employees, affiliates and contractors are not responsible for any content, associated links, resources, or services associated with a third-party website. newbiotechstock.com uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. In no event shall newbiotechstock.com, its owners, directors, officers, employees, affiliates and contractors be liable (jointly or severally) for any special, incidental, indirect or consequential damages of any kind, or any damages whatsoever resulting from loss of use, data or profits, whether or not advised of the possibility of damage, and on any theory of liability, arising out of or in connection with this website/newsletter. You agree to hold newbiotechstock.com, its owners, directors, officers, employees, affiliates and contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of the information contained on this website/newsletter (including any loss or damage of any sort associated with your use of third party content). You agree that use of this website/newsletter is at your sole risk. newbiotechstock.com disclaims all warranties of any kind, express or implied. If any applicable authority holds any portion of this section to be unenforceable, then liability will be limited to the fullest possible extent permitted by applicable law. newbiotechstock.com encourages readers to invest carefully, and read investor and issuer information available at the websites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov . In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/investors/index.htm.Questions regarding any information contained on this website/newsletter may be sent to mail@newbiotechstock.com. To review newbiotechstock.com’s website and its disclaimer, please visit www.newbiotechstock.com

Prev1 of 2
Use your ← → (arrow) keys to browse

Breaking

Quanta’s Polarized CBD: Where Plants Meet Quantum Physics

Published

on

CBD, the short name for cannabidiol, remains a hot topic today in the consumer and investment spaces.  Companies are packing the component of hemp and cannabis touted for its powerful positive benefits into a litany of products, ranging from creams to gummies to medicines to food and beverages and everywhere in between.  Why?  Because consumer demand is soaring and the recent passage of the Farm Bill made hemp-derived CBD completely legal, opening up interstate commerce without fears of prosecution.

CBD, which doesn’t contain any of the psychoactive components that result in the “high” frequently associated with cannabis, has a therapeutic index that goes from alleviating symptoms of hard-to-treat diseases like epilepsy to anti-aging skin properties.

This segment of the so-called “green rush” – used to describe cannabis reform sweeping the planet – could be growing faster than the legal marijuana market.  Owing to increased consumer awareness about CBD’s uses and safety profile and relaxed hemp regulations, industry analysts at the Brightfield Group forecast that the hemp-derived CBD market could swell to $22 billion by 2022 from about $580 million in 2018.

At Quanta, Inc. (OTC: QNTA), scientists are using quantum physics to manipulate and stabilize electron spin in naturally occurring elements, including CBD, to increase performance in the body.  The result is CBD that is “polarized,” which brings with it a bevy of benefits that essentially amplify the properties of CBD in a consistent and repeatable fashion.  This means products using polarized CBD are faster acting with stronger healing power that last longer without making a person tired compared to competitor’s products.

Many companies tout increased “bioavailability,” meaning that the active ingredient in their product reaches its target in a more efficient way.  Others have trumpeted innovation in increasing bioenergy (or bio-activity), increasing the physical energy and effectiveness of any percentage of CBD available. 

Burbank, California-based Quanta takes it a step further, saying that its technology is the first to “increase and sustain” bio-activity in CBD.  The applied science company’s flagship product is a muscle rub, a combination of 13 natural ingredients, including, but not limited to, CBD, arnica, turmeric, ginger and sunflower oil.  Aptly branded as “Quanta CBD Muscle Rub,” the proprietary blend of the ingredients maximizes anti-inflammatory relief and circulation while easing aches and pains in muscles and joints for comfort and overall well-being.

Quanta also sells an ultra-premium CBD vape cartridge containing hemp-derived CBD.

According to Quanta, sales of the premium organic rub are improving dramatically since the initial launch just over five months ago.  The company sells the balm through its ecommerce channels in addition to being available in more than 300 doctor’s offices, 100 pharmacies and over 150 retail shops.

Quanta CEO Eric Rice didn’t provide specifics, but did say earlier this month that the muscle rub has built a loyal customer base that has helped bolster sales 70% month-over-month since launch.

Rice added that they are working on adding more distribution partners, including ongoing discussions with several national fitness centers, hospital networks and pain management centers.  The company is also planning to add more products to the portfolio using its polarization technology, for which it will manufacture its own line of CBD products in-house.  The company made the shift in business model from licensing CBD brands to the more lucrative model of manufacturing its own products subsequent to the passing of the Farm Bill.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third-party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from a third-party for content creation, advertising and distribution services related to this material.

Continue Reading

Breaking

MassRoots Expands Product Portfolio with New Partner and Acquisition of COWA Science

Published

on

With predictions that the legal cannabis market will experience non-linear growth in the coming years underscored by ongoing legalization of marijuana worldwide, companies big and small are hustling to build their footprints to capture share in a market that  Grand View Research forecasts will reach $146.4 billion by the end of 2025 (from $7.1 billion in 2016).  Whether companies are touching the once-taboo plant or operating in an ancillary segment, there is no shortfall of growth opportunities as part of an abolishment of eight decades of cannabis prohibition.

For its part, MassRoots (OTCQB: MSRT), a technology and rewards platform at its core, is branching out into different verticals.  Since the start of 2019, the company has penned two substantive agreements that have expanded MassRoots’ portfolio of products and services.

In mid-January, the Los Angeles-based company partnered with We are Kured, a subsidiary of New Age Brands (CSE: NF)(OTC:NWGFF), to serve as the leading online retailer of We are Kured’s best-selling CBD Pen.   The handheld vaporizer pen dispenses cannabidiol, or CBD, a THC-free constituent of hemp and cannabis trumpeted for its therapeutic benefits relating to alleviating inflammation, pain, anxiety, seizures and a host of other symptoms from a variety of maladies without unpleasant side effects or psychotropic buzz often associated with marijuana. 

The pen represents a new revenue stream for MassRoots as the first CBD product to be sold directly through the company’s online platform and social media pages.  MassRoots has more than one million social media followers, in excess of 750,000 email subscribers and hundreds of thousands of unique monthly visitors on its website and application to whom it can market the product.

This month, MassRoots entered a definitive agreement to acquire supply-chain as a service company COWA Science Corp. in an all-stock deal valued at approximately $5.78 million.  The buyout terms are dependent upon COWA Science meeting annual revenue milestones of $2.5 million and $7.5 million, as well as other customary closing conditions.  In short, the terms specify that COWA shareholders are entitled to additional shares if the sales milestones are hit within three years of the effectiveness of the merger.

For 2018, unaudited financials show COWA Science generated revenue of approximately $1.5 million by providing a variety of products and services to its list of about 50 cannabis- and hemp-focused clients.  Upon completion of the transaction, COWA will become a wholly-owned subsidiary of MassRoots.

MassRoots expects the acquisition to be immediately accretive while diversifying its business.  Management expects to build upon the existing COWA Science business to offer a complete cannabis-centric suite covering the full supply chain, including advertising, consumer packaging, process and product development, growing supplements and nutrients, HVAC and more.  On the whole, the new, bigger MassRoots intends to provide a broad mix of offerings to hundreds of licensed cannabis business in key markets across the country.

“Going forward, MassRoots is confident that the addition of COWA Science will increase overall revenues and expand our market presence, with the goal of generating positive cash-flows from operations,” commented MassRoots CEO Isaac Dietrich in the press release on the acquisition.  Dietrich added that the decision to bring COWA Science under his company’s umbrella came after several years of following their business and growth trajectory.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third-party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from a third-party for content creation, advertising and distribution services related to this material.

Continue Reading

Breaking

After a Solid 2018, BioSig Looks to Continue Success in 2019

Published

on

2018 may have been a tough year for the markets, but it certainly wasn’t for BioSig Technologies (NASDAQ: BSGM), as the little company grew up in a big way.  The fundamental advancements were rewarded by stockholders, evidenced by the shares of BSGM appreciating by 21.3% in 2018. 

Shareholders had plenty of cause to applaud BioSig for a litany of accomplishments.  For starters, the medical device maker graduated from the over the counter markets to a senior exchange, listing on the Nasdaq Capital Market in September.  Further, BioSig raised $13.5 million in quality capital to fund the next steps in expanding the pipeline and commercializing its PURE EP™ System.  The company now has almost 3,400 shareholders.

PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms, including Atrial Fibrillation and Ventricular Tachycardia. In September, the FDA granted 510(k) clearance to BioSig for PURE EP, effectively giving the green light for commercialization of the cutting-edge system.

Some of the finest cardiac medical centers in the world are involved with PURE EP System, namely Mayo Clinic and Texas Cardiac Arrhythmia Institute.  These venerable institutions have signed agreements with BioSig for the first commercial installations of the systems.  17 pre-clinical studies of PURE EP System included other upper echelon institutions, such as Mount Sinai and UCLA medical centers.

All of this research and preparation laid the groundwork for BioSig to conduct the First-in-Human study of PURE EP System, which is expected this quarter and will be hosted by Mayo Clinic and Texas Cardiac Arrhythmia Institute.  This is a critical component of commercialization, with other leading centers expected to install the system and provide feedback subsequent to the human study.  This information is part of a methodical approach that will allow BioSig to be properly positioned to ramp-up commercialization efforts in 2020.

To that point, results from the human trial is planned to be presented in May at Heart Rhythm Scientific Sessions, the largest event in BioSig’s industry, where the company can show-off its technology to a large community of potential customers.

Looking further down the road, Mayo Clinic has come on as a strategic collaborator to explore other indications and applications where PURE EP System could prove valuable in treating patients with different diseases and conditions.

BioSig also expanded its global footprint as it looks ahead to commercialization of PURE EP System and future innovation.  New hubs were opened in Austin, Texas and Norwalk, Connecticut, joining the corporate headquarters in Santa Monica, California and rep office in Geneva, Switzerland.

Internally, the company is stronger than ever with the formation of an Advisory Board made up of seasoned veterans lending their expertise in finance, commercialization, government affairs, capital markets, clinical fields and strategic partners.

Backstopped by these developments and upcoming milestones, ROTH Capital Partners has given BSGM a “Buy” rating with a price target of $14.00 per share.  After closing December 31, 2018 at $4.27, shares are up 19.9% so far in 2019 as of the close of trading on Friday, February 15, 2019, meaning ROTH sees a lot more upside to BioSig as commercialization of PURE EP System draws closer.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third-party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from a third-party for content creation, advertising and distribution services related to this material.

Continue Reading

Most Popular